2023
Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis
Ito S, Laham R, Nkomo V, Forrest J, Reardon M, Little S, Mumtaz M, Gada H, Bajwa T, Langholz D, Heiser J, Chawla A, Jenson B, Attizanni G, Markowitz A, Huang J, Oh J. Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis. Open Heart 2023, 10: e002297. PMID: 37173100, PMCID: PMC10186477, DOI: 10.1136/openhrt-2023-002297.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisAortic valve replacementAortic stenosisSymptomatic patientsValve replacementKansas City Cardiomyopathy Questionnaire overall summary scoreEvolut Low Risk trialSurgical aortic valve replacementLow-risk trialsLow-risk patientsOverall summary scoreRate of deathQuality of lifeDisabling strokeEchocardiographic evidenceIsolated AVRHaemodynamic profileClinical outcomesHaemodynamic outcomesRisk trialsClinical trialsCalcium volumeSummary scoresPatientsCore laboratory measurements
2021
Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial
Wang L, Lu Y, Wang H, Gu J, J Z, Lian Z, Zhang Z, Krumholz H, Sun N. Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial. Open Heart 2021, 8: e001719. PMID: 34580169, PMCID: PMC8477318, DOI: 10.1136/openhrt-2021-001719.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntihypertensive AgentsBlood PressureCardiography, ImpedanceChinaClinical Decision-MakingFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMiddle AgedPractice Guidelines as TopicRetrospective StudiesTherapy, Computer-AssistedTime FactorsTreatment OutcomeYoung AdultConceptsBody mass indexPeking University People's HospitalStandard care groupBlood pressure controlSystolic BPHaemodynamic groupsTreatment strategiesImpedance cardiographyBaseline BPBP goalHypertension clinicHaemodynamic profileBP levelsCare groupPeople's HospitalMean baseline systolic BPPressure controlReal-world clinical practiceBaseline systolic BPMean systolic BPDiastolic BP levelsProportion of patientsPragmatic clinical trialsReal-world populationBaseline DBP
2014
Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
Fischer A, Swigris J, Bolster M, Chung L, Csuka M, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers L, Gomberg-Maitland M, Mathai S, Simms R, Steen V. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clinical And Experimental Rheumatology 2014, 32: s-109-14. PMID: 25372796.Peer-Reviewed Original ResearchConceptsSeverity of ILDHaemodynamic parametersNew York Heart Association functional class IIFunctional class IILeft heart diseasePulmonary vascular diseasePulmonary function testingInterstitial lung diseaseImpact of extentMajority of subjectsHRCT evidenceILD extentILD severityPH-ILDSSc-ILDPulmonary hypertensionBaseline characteristicsHaemodynamic profileCutaneous SScHRCT scansFunction testingLung diseaseVascular diseaseHeart diseasePulmonary physiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply